Clinical trial Recruiting at 1 site Observational Ages 18 and up

TSLP in asthma: comparing long and short forms in adults with atopic or severe asthma

Official title: TSLP and Its Isoforms (Short and Long Form TSLP) in Different Asthma Phenotypes

Run by Medical University of Warsaw · NCT07786870 · Data updated 2026-11-12

Researchers are testing whether levels of two TSLP forms in adults with asthma relate to disease severity and airway inflammation.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment70 (estimated)
SponsorMedical University of Warsaw
Academic / other
Drugs / interventionsomalizumab, mepolizumab, reslizumab, dupilumab, tezepelumab
Locations1 site (Warsaw, Warsaw)
StatusRecruiting
StartedApril 30, 2024
Main results expectedNovember 2026
Study endsNovember 2026
Registry record updatedAugust 26, 2026
Trial IDNCT07786870 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with diagnosed atopic or severe persistent asthma, not currently on monoclonal antibody therapies, and without major exclusion criteria.

Probably not a fit

Patients with non-asthma respiratory diseases, active infections, recent antibiotics, or current biologic therapy may not benefit from this observational analysis.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will measure and compare the long and short forms of thymic stromal lymphopoietin (TSLP) in adults with asthma. Participants will be adults 18 and older with atopic or severe persistent asthma and will not receive any experimental treatment. Data will come from baseline observations of airway samples and clinical information to explore associations between TSLP isoforms and asthma characteristics. The study is conducted at the Medical University of Warsaw in Poland without an active interventional component.

Why it matters

Potential benefit: If successful, the study could improve understanding of how TSLP forms relate to asthma severity and potentially guide future therapies.

How similar studies have gone: Previous research has linked higher TSLP levels to worse asthma control, supporting the relevance of studying TSLP isoforms in this population.

Who can join: the full rules

Show full inclusion / exclusion criteria
1. Inclusion criteria

   * age \> 18 years, without the upper age limit,
   * asthma (diagnosis in accordance with the GINA 2023 guidelines),
2. Exclusion criteria

   * other respiratory diseases (e.g., chronic obstructive pulmonary disease \[COPD\]);
   * active cigarette smoking or a smoking history of \>10 pack-years;
   * active malignancy;
   * active pulmonary tuberculosis or active respiratory tract infection;
   * use of antibiotics within 4 weeks prior to study enrollment;
   * current long-term home oxygen therapy (\>15 hours per day);
   * current treatment with monoclonal antibody therapies (e.g., omalizumab, mepolizumab, reslizumab, dupilumab, tezepelumab, or other biologics);
   * pregnancy.

Where it's running

  • Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Warsaw, Poland,
    Warsaw, Warsaw, Poland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.